Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Moderna (NASDAQ:MRNA), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the ...

Moderna currently has two marketed vaccines in its portfolio — the COVID-19 vaccine Spikevax and the recently launched respiratory syncytial virus (RSV) vaccine mResvia. Product sales were down ...

Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter.

The COVID vaccine Spikevax is one of Moderna's two approved products, along with mRESVIA, a vaccine for respiratory syncytial virus, or RSV. Sales of Spikevax came to $923 million, to account for ...

Moderna is entering 2025 with two approved products, Spikevax® and mRESVIA®. COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 ...

The quarter saw Moderna begin transitioning its revenue base as COVID-19 vaccine sales tapered due to changing market dynamics. Spikevax sales alone contributed $923 million in the quarter ...